Iatrogenic systemic lymphedema following multiple myeloma treatment

S. Radu, J. Wilson, A. K. Bagwell, G. Meyers, A. C. Nauta

Research output: Contribution to journalReview articlepeer-review


Lymphedema is a debilitating disease characterized by abnormal lymphatic drainage, either due to primary maldevelopment of the lymphatic system or to secondary injury. The clinical features of primary and secondary lymphedema differ, with primary lymphedema more often involving progressive bilateral lower extremity disease as compared to secondary lymphedema characteristically having more localized symptoms related to the origin of injury. This case presentation describes a patient who presented with bilateral lower extremity swelling, left greater than the right, with imaging results to support the diagnosis of lymphedema. During the time he was followed in our clinic, our team witnessed rapid progression of his lymphedema despite compliance with conservative management. We believe that the primary mechanism of systemic damage to our patient's lymphatic system is the lenalidomide and bortezomib therapy prescribed to treat multiple myeloma. This review explores the relationship between lenalidomide, bortezomib, and lymphedema in efforts of understanding this unique pathology of iatrogenic lymphedema mimicking primary nature.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
Issue number3
StatePublished - 2022


  • bortezomib
  • chemotherapy
  • iatrogenic lymphedema
  • lenalidomide
  • multiple myeloma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Hematology


Dive into the research topics of 'Iatrogenic systemic lymphedema following multiple myeloma treatment'. Together they form a unique fingerprint.

Cite this